Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Timolol
Drug ID BADD_D02219
Description Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes.[L6724] It is also used in tablet form as a drug to treat hypertension.[L6727] Timolol was first approved by the FDA in 1978.[L6724] This drug is marketed by several manufacturers [L6736] and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
Indications and Usage In its oral form it is used to treat high blood pressure and prevent heart attacks, and occasionally to prevent migraine headaches. In its opthalmic form it is used to treat open-angle and occasionally secondary glaucoma.
Marketing Status Prescription; Discontinued
ATC Code C07AA06; S01ED01
DrugBank ID DB00373
KEGG ID D00378
MeSH ID D013999
PubChem ID 33624
TTD Drug ID D05UVD
NDC Product Code 17478-365; 76478-002; 17478-366; 76478-001; 17478-189
Synonyms Timolol | Timolol Maleate | Timolol Maleate, (1:1) Salt | (S)-1-((1,1-Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadazol-3-yl)oxy)-2-propanol | 2-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, (S)- | Timoptic | Timoptol | Timacar | Timolol Hemihydrate | Blocadren | L-714,465 | L 714,465 | L714,465 | MK-950 | MK 950 | MK950 | Optimol
Chemical Information
Molecular Formula C13H24N4O3S
CAS Registry Number 26839-75-8
SMILES CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sinoatrial block02.03.01.010--Not Available
Sinus arrest02.03.03.0070.000439%Not Available
Sinus bradycardia02.03.03.0090.001317%
Sinusitis22.07.03.007; 11.01.13.005--
Sjogren's syndrome15.06.01.015; 10.04.04.009; 07.06.01.010; 06.08.02.011--Not Available
Skin disorder23.03.03.007--Not Available
Skin irritation23.03.04.009--Not Available
Somnolence19.02.05.003; 17.02.04.0060.000439%
Stillbirth18.01.02.002; 08.04.01.0060.000172%Not Available
Strangury20.02.02.017--Not Available
Supraventricular extrasystoles02.03.03.0110.000658%Not Available
Syncope02.01.02.008; 24.06.02.012; 17.02.04.0080.000878%
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Tachypnoea22.02.01.0140.000439%Not Available
Tension19.06.02.005--Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.003--Not Available
Thrombosis24.01.01.0060.000439%Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tremor17.01.06.0020.000658%
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urticaria23.04.02.001; 10.01.06.001--
Ventricular extrasystoles02.03.04.0070.000439%Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.0070.003292%
Visual acuity reduced17.17.01.011; 06.02.03.0010.001097%
Visual field defect17.17.01.001; 06.02.07.0030.000439%Not Available
Visual impairment06.02.06.0080.000658%Not Available
Vital dye staining cornea present13.07.04.010--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
The 6th Page    First    Pre   6 7 8    Next   Last    Total 8 Pages